#United States #New York #class action lawsuit #Pomerantz LLP #Actinium Pharmaceuticals

Investor Alert: Actinium Pharmaceuticals Class Action Lawsuit

Pomerantz LLP has recently filed a class action lawsuit against Actinium Pharmaceuticals, Inc. (NYSE: ATNM), aimed at safeguarding the rights of investors facing significant losses due to potential securities fraud or unlawful business practices. This alert serves as a reminder for affected investors to be proactive in addressing this situation, as critical deadlines are fast approaching.

Key Details of the Lawsuit

Investors who suffered losses in their investments are encouraged to contact Danielle Peyton at Pomerantz LLP to discuss their options. Whether you purchased or acquired Actinium securities during the specified class period, you must express your interest before May 26, 2025, to be considered for the position of Lead Plaintiff in the lawsuit.

The lawsuit revolves around a concerning announcement made by Actinium on August 5, 2024. In the press release, the company revealed that the U.S. FDA had determined that the Phase 3 SIERRA trial was insufficient to support a Biologics License Application (BLA) for their drug candidate Iomab-B, used for treating active relapsed or refractory acute myeloid leukemia. This news led to a drastic decline in Actinium's stock price, dropping nearly 60% in a single day, closing at $2.48 per share.

Such dramatic movements in stock prices raise red flags and could indicate possible misrepresentation or omissions by the company regarding the viability of their product and the integrity of their business practices.

Background on Pomerantz LLP

Founded by the renowned Abraham L. Pomerantz, the firm has an established history in particularly corporate, securities, and antitrust litigation. With over 85 years of experience, Pomerantz has successfully recovered millions on behalf of class members. Their commitment to pursuing justice for victims of corporate misconduct reflects their standing as a premier law firm in this area.

Importance of Acting Quickly

It is important for investors who believe they have been wronged to act swiftly. The potential to join the class action and the chance to recover losses hinges on timely communication with Pomerantz LLP. For those interested, it is advisable to provide pertinent information, including mailing address, phone number, and details of purchases, to streamline the engagement process.

Contact Information

For further inquiries, investors should reach out via email at [email protected] or via phone at 646-581-9980, extension 7980. This opportunity to join a class action lawsuit should be taken seriously, as it may significantly impact the recovery of losses for affected investors.

In summary, the class action lawsuit filed against Actinium Pharmaceuticals highlights potential significant issues within the company’s governance and its communication with investors. Those involved should stay informed of developments in the case and consider the implications it may have on their investments.

For more information and updates, please refer to Pomerantz's official site at www.pomerantzlaw.com.